CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a patient's own immune T cells and engineering them to recognize specific targets ...
Hosted on MSN1h
Canaccord Genuity Downgrades Intra-Cellular Therapies (ITCI)Fintel reports that on January 31, 2025, Canaccord Genuity downgraded their outlook for Intra-Cellular Therapies ...
Findings indicate that altering glucose metabolism in T cells boosts their therapeutic potential against melanoma, paving the ...
Canaccord Genuity analysts downgraded Intra-Cellular Therapies (NASDAQ:ITCI) stock from Buy to Hold, adjusting the price target to $132 from the previous $119. The revision follows the recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback